ABSTRACT
Objective:To correlate the expression of microRNA (miRNA)-21 and miRNA-335-5p with pepsinogen and gastrin-17 in patients with gastric cancer.Methods:Sixty-one patients with gastric cancer who received treatment in Linhai Second People's Hospital between January 2019 and January 2021 were included in the patient group. An additional 60 healthy patients who concurrently received physical examination were included in the control group. Serum pepsinogen I, pepsinogen II and gastrin-17 levels were determined by latex-enhanced immunoturbidimetry. miRNA-21 and miRNA-335-5p expression were determined by quantitative reverse transcription-polymerase chain reaction. Serum pepsinogen I, pepsinogen II and gastrin-17 levels and miRNA-21 and miRNA-335-5p expression were compared between the two groups. The sensitivity and specificity of miRNA-21 and miRNA-335-5p in the diagnosis of gastric cancer were analyzed. The correlation between miRNA-21 and miRNA-335-5p expression and pepsinogen I, pepsinogen II and gastrin-17 levels was analyzed.Results:Serum pepsinogen I and gastrin-17 levels in the patient group were (54.36 ± 9.89) μg/L and (13.74 ± 1.89) pg/mL, respectively, which were significantly lower than those in the control group [(112.31 ± 23.24) μg/L, (18.75 ± 2.36) pg/mL, t = 17.89, 12.90, both P < 0.05]. Serum pepsinogen II level in the patient group was significantly higher than that in the control group [(24.35 ± 4.53) μg/L vs. (20.37 ± 3.28) μg/L, t = 5.52, P < 0.05]. The relative mRNA expression of miRNA-21 in the patient group was significantly higher than that in the control group [(3.42 ± 0.61) vs. (0.53 ± 0.12), t = 30.01, P < 0.05]. The relative mRNA expression of miRNA-335-5p in the patient group was significantly lower than that in the control group [(0.32 ± 0.17) vs. (1.65 ± 0.35), t = 26.65, P < 0.05]. The receiver operating characteristic curve analysis showed that the sensitivity and specificity of miRNA-21 in the diagnosis of gastric cancer were 74.36% and 68.18%, respectively, and they were 79.49% and 60.90% for miRNA-335-5p, respectively. There was a negative linear correlation between miRNA-21 and pepsinogen I and gastrin-17 levels ( r = -0.82, -0.74), but there was a positive linear correlation between miRNA-21 and pepsinogen II levels ( r = 0.76). There was a positive linear correlation between miRNA-335-5p and pepsinogen I and gastrin-17 ( r = 0.79, 0.72), but there was a negative linear correlation between miRNA-335-5p and pepsinogen II levels ( r = -0.70). Conclusion:miRNA-21 is highly expressed in patients with gastric cancer, while miRNA-335-5p is lowly expressed. miRNA-21 and miRNA-335-5p are highly correlated with pepsinogen and gastrin-17 levels. miRNA-21 and miRNA-335-5p can be used as effective indices for diagnosis of gastric cancer. Findings of this study are highly innovative and scientific.
ABSTRACT
Objective In order to detect gastric fluid pH value,Gastrin-17 (G-17),pepsinogen Ⅰ (PGⅠ),pepsinogen Ⅱ (PGⅡ) and figure out gastric secretory function in patients of functional constipation (FC).Methods 51 healthy individuals were chosen as control group and 42 patients with FC were chosen as FC group,of which serum gastric fluid pH value,Hp ratio,G-17,PGⅠ and PGⅡ were detected and analyzed.Results Compared with control group,gastric fluid pH value were marked reduced (t=2.180,P=0.032),and G-17,PGⅠ level in blood were marked increased in FC group (G-17:t=2.703,P=0.008;PGⅠ:t=7.388,P＜0.001).Hp ratio and blood level of PGⅡ in two groups showed no significant difference (Hp ratio:x2=0.031,P=0.861;PGⅡ:t=1.666,P=0.100).Conclusion Increased gastric secretory function level were found in patients of functional constipation.It gave a hint that stimulated gastroenteritic axis existed in patients of functional constipation.
ABSTRACT
Objective To discuss the application value of serum pepsinogen Ⅰ(PGⅠ),carcinoembryonic antigen(CEA) and gastrin-17(G-17) in assessment of chemotherapy curative effect in patients with gastric cancer.Methods From Feb.2014 to Jun.2016,a total of 90 patients with gastric cancer were selected,and treated with docetaxe/cisplatin/5-fluorouracil(DCF) scheme for two courses.All patients were divided into effective group and ineffective group,according to the assessment criterion,proclaimed by World Health Organization.Serum levels of CEA,PGⅠand G-17 were detected before and after treatment.Curative effect was also assessed according to the changes of CEA,PGⅠand G-17.Receiver operating characteristic curve(ROC curve) was used to analyze the performance of PGⅠ,CEA and G-17 in the assessment of curative effect.Results Chemotherapy was effective in 29 cases,accounting for 32.22%.After chemotherapy,serum CEA and G-17 level of effective group were lower than ineffective group,while PGⅠ level was higher(P<0.05).ROC curve analysis showed that the area under ROC curve,sensitivity and specificity of combined detection for the assessment of curative effect were higher than single detection of serum PGⅠ,CEA and G-17,taking 70 g/L,7.35 g/L and 14.22 pmol/L as cut-off value(P<0.05).Conclusion Combined detection of serum PGⅠ,CEA and G-17 could be with high accuracy,specificity and sensitivity for the assessment of chemotherapy effect in patients with gastric cancer.
ABSTRACT
Objective To use the colloidal gold immunochromatography (GICA ) method to conduct the methodological prelimi-nary evaluation on pepsinogen Ⅰ (PGI) reagent kit .Methods The method provide by the Preliminary Evaluation of Clinical Quan-titative Experimental Methods :Approval Guide Second Edition (EP10-A2) formulated according to the Clinical Laboratory Stand-ards Institute (CLSI) was used to continuously detect the low ,moderate and high concentrations of serum for 5 d ,Then the related data were collected for analyzing the dispersion degree ,linearity ,offset ,precision and so on .Results The PGⅠ quality control ser-um (concentration 25 ,50 ,100 μg/L) was detected at low ,medium and high concentration levels ,the linear regression equation ob-tained by analysis was Y=0 .9939X+0 .7433 ,correlation coefficient (R2 )=0 .9992 ;the offsets were 0 .37 ,0 .77 ,0 .78 μg/L re-spectively ,total imprecision was 3 .04% ,1 .17% and 1 .08% respectively .Conclusion The GICA related technical indicators of PGⅠreagent kit reach the standards of EP10-A2 document ,the detection results are accurate with high sensitivity and good stability , and conform to the requirements of clinical applications .
ABSTRACT
Objective To evaluate the clinical application value of flow fluorescence assay in determination of serum pepsinogenⅠ and Ⅱ.Methods The precision of flow fluorescence assay in the detection of serum pepsinogen Ⅰ and Ⅱ were evaluated. Methodology comparison were conducted between flow fluorescence assay and enzyme-linked immunosorbent assay(ELISA)kit through detecting clinical samples.The reference ranges for PGⅠ and PGⅡ/PGⅠ ratio of healthy population were established. The levels of PGⅠand PGⅡ/PGⅠ ratio were detected in serum samples of patients suffering superficial gastritis,atrophic gastritis and gastric cancer.Results The within-run and between-run coefficient of variation of PGⅠ were 4.26%-5.35% and 6.73%-7.75%,respectively.And those of PGⅡ were 5.48% - 6.42% and 8.46% -8.85%,respectively.Methodology comparison be-tween flow fluorescence assay and ELISA demonstrated good linear correlations.The linear equation wasY =0.91 1X -22.635(r=0.966,P <0.05)and Y =0.892X -0.548(r=0.980,P <0.05)for PGⅠ and PGⅡ,respectively.The lower limit of the reference range of PGⅠ and PGⅡ/PGⅠ ratio were 32.77 ng/mL and 4.1 6,respectively.The PGⅠ and PGⅠ /PGⅡ ratio of patients suf-fering atrophic gastritis and gastric cancer were statistically significantly lower than those in patients suffering superficial gastritis (P <0.05).Conclusion The flow fluorescence assay could conduct simultaneous detection of PGⅠ and PGⅡwith good methodo-logical performance and high efficiency.The determination of PGⅠ and PGⅡlevels through flow fluorescence assay could provide laboratory basis for the screening and diagnosis of atrophic gastritis and early gastric cancer.
ABSTRACT
A dual-label time-resolved fluoroimmunoassay was established for simultaneously detecting pepsinogen Ⅰ (PGⅠ) and pepsinogen Ⅱ (PG Ⅱ) in human serum. Two capture monoclonal antibodies, 8003# of PGⅠ and 8101# of PGⅡ, were co-coated in 96 microtitration wells. The counterpart tracer monoclonal antibodies, 8016# of PGⅠ and 8102# of PGⅡ, were labeled with Eu3+ and sm3+-chelates, respectively. The samples were assayed by one-step sandwich protocol with the time-resolved fluorometry. The measurement ranges of PGⅠ were 0.2～300.0 ?g/L with the within-run and between-run precision was 5.2% and 8.1%, and that of PGⅡ were 0.05～55.0 ?g/L with the within-run and between-run precision was 7.1% and 11.7%, respectively. The average recovery rates of PGⅠ and PGⅡ were 96.9% and 103.7%, respectively. The results obtained by the dual-label assay agreed well with those by enzyme-linked immunosorbent assays of PGⅠ and PGⅡ, whose correlation ratio were 0.9426 of PGⅠ and 0.9396 of PGⅡ, respectively. The means of 300 healthy volunteers were (157.3 ? 51.0) ?g/L for serum PGⅠ,(10.6 ? 5.9) ?g/L for serum PGⅡ, and (14.8 ? 4.3) for the PGⅠ/PGⅡ ratio. The normal ranges of serum PGⅠ levels for healthy volunteers were 55.3～259.3 ?g/L, those of serum PGⅡ levels were less than 23 ?g/L, the PGⅠ/PGⅡ ratio was more than 6. The proposed dual-label TRFIA for simultaneous detection of PGⅠ and PGⅡ is a simple, sensitive, and rapid method. It could provide serology high-screening of the samples for gastric diseases and would allow investigations into the possible diagnostic value of analysis in various clinical condition.